Tuberculosis (TB) is a very common infection in India that is also very contagious. When an infected person sneezes or coughs, air particles containing the TB bacteria (Mycobacterium tuberculosis) can easily spread from person to person. each infected person can infect up to another 10 people each year.  the symptoms and signs of TB can vary, depending on the organ(s) that is affected by the bacteria. TB most commonly nests in the lungs but can also affect the kidneys, bones and brain.

According to WHO, TB accounts for about 20% of the global TB cases. each year, about 2 million people in India develop TB, and  over 300,000 die because of it.

.Anyone can catch TB, especially if they are in a closed space with the affected person.  the unaffected person inhales droplets with bacteria and these bacteria reach the lungs.  here, the person’s immune system can fight against the bacteria.  If successful, the bacteria will remain in the lungs but will be “latent” (inactive and not causing any problems at the present).  If the immune system is not successful in containing the bacteria, then an active case of TB can develop.  Once the bacteria invade the body and overwhelm the immune response of the body, they can also find their way to various organs through the blood stream.

People with a latent TB infection don’t have any symptoms, don’t feel sick, cannot infect others but they have a positive skin test (Mantoux Test) since antibodies (defenses) to the bacteria were formed at the time of the initial infection.  Up to one-third of the world’s population is considered to have latent TB infections, as estimated by the World Health Organization (WHO) in 2008.  Treating latent TB is important.  a latent infection can be activated, especially if your immune system is weakened for any reason, including nutritional deficiencies or infection with HIV.

In the case of an active infection, signs and symptoms vary according to the organ which is affected. When the lungs are infected, signs and symptoms of TB are:

1. A cough persisting for 2 to 3 weeks and beyond, which is usually worse in the mornings
2. Chest pain
3. Blood in the sputum (the mucus and saliva produced when coughing or clearing throat)
4. Breathlessness

Back pain may be caused by tuberculosis of the spine, and blood in the urine may be caused by tuberculosis in your kidneys.  TB in the brain can cause headaches, a stiff neck, confusion, vomiting, an altered mental state, seizures and other signs and symptoms related to the nerves.

In general, a person with active TB in any organ may have these signs and symptoms:

1. Weakness
2. Feeling tired
3. Weight loss
4. Loss of appetite
5. Chills
6. Fever
7. Sweating in the nighttime while sleeping, even if the weather is cold

If you or someone you know is experiencing any of these symptoms, or has reason to think they have been exposed to TB then one should seek consultation from a healthcare worker and the public health authorities.  These healthcare workers will perform one of two tests: a test on the skin and one of the sputum (mucus produced when coughing).  for those people who have had the BCG vaccine against TB, which is mandatory at birth in India, may have a “positive” skin test despite not being infected with TB  the skin test will need to be re-examined two days after it is given.  If a sputum sample is provided, the results may take longer as they need to be sent for laboratory work.

DUBLIN–(BUSINESS WIRE)–Research and Markets (researchandmarkets.com/research/3b0638/prostate_cancer) has announced the addition of GlobalData ‘s new report “Prostate Cancer – BRIC Drug Forecasts and Treatment Analysis to 2020″ to their offering.

“Prostate Cancer – BRIC Drug Forecasts and Treatment Analysis to 2020”

our pharmaceutical report, Prostate Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020 is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. the report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. it identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. it analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. the report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. the report provides valuable insights into the pipeline products within the global prostate cancer sector. it quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.

the scope of the report includes:

the report will enhance your decision making capability. it will allow you to:

• Develop business strategies and perform superior market quantification analysis by – Understanding the trends shaping and driving the Japanese prostate cancer therapeutics market. – Understanding the treatment preferences of physicians according to disease state and across treatment flow. – Assessing market sizing, forecasts and quantified growth opportunities in the BRIC prostate cancer therapeutics market up to 2020. – Quantifying the patient population in the BRIC countries to better design product pricing and launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by – Performing benchmarking analysis and growth opportunities against currently marketed products. – Identifying market entry points based on safety, efficacy and pricing parameters. – Assessing competitiveness of products in market by understanding the strength and weakness of the current competition.
• Develop and design your in-licensing and out-licensing strategies by – Taking a comprehensive look of at the disease pipeline and identifying the most promising paradigm shifting products. – Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

Prostate Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020 is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. the report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. it identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. it analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. the report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. the report provides valuable insights into the pipeline products within the global prostate cancer sector. it quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

the Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy

the authors analysis finds that the prostate cancer therapeutics market in BRIC (Brazil, Russia, India and China) is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. the growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. the patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. the annual cost of prostate cancer therapy between 2001 and 2009 was driven by increased uptake of chemotherapy using Taxotere. Expected launch of new therapies such as Provenge (sipuleucel-T) and Jevtana (cabazitaxel) will further drive the annual cost of therapy.

Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. the introduction of new therapies for metastatic prostate cancer is expected to expand the market further.

• 1 Overview
• 2 Disease Overview
• 3 Market Characterization
• 4 Competitor Assessment
• 5 Pipeline Assessment
• 6 Unmet need and Target Product Profile
• 7 Strategic Assessment
• 8 Company Profiles
• 9 M&A Analysis
• 10 Appendix

Companies Mentioned:

For more information visit researchandmarkets.com/research/3b0638/prostate_cancer.

Hi, I am Pernita from India, I was diagnosed with ulcerative colitis about three years back. I am a mother of two young kids.  I was on wysalone tablets 60 mg for two years , whenever i was told to taper it off my condition became worse. i think my system started depending on it a lot. my doc wanted to put me on azoran but my hemoglobin fell to 4 and had to go for transfusion . it raised to 7 and finally with amway folic subsitutes I tried to raise it to 11 . finaly 5 months back it raised and i was put on azoran. but as told by the doctor that it will react in 3 months approximately… I waited . But nothing happened.  I developed fissures as was taking enemas too. every thing became painful. was on 25 mg wysalone , 1500 mg rowasa three times a day (4500) , three azaron, codine sulfate three times a day, twice enema and my system gave up.  Had no energy left to face the day. Blood was spurting out on every trip to loo. the pain was unbearable. was even getting cluster head aches ev ery two three days. Then worst came my skin started getting boils. they were full of mucus and left deep holes all over my waist line. As i was trying to treat one the other came up next day. that was where i became totaly fed up. in us hindus we are told . God gives you that much pain which you can bear. i started crying looking at myself in mirror and trying to tell the al mighty above that he made mistake in ng to bear all.judging me. am not that strong enough. Went to my doc and told him that am going off arozan and tapering off most of the drugs as they are nt working. he told me to continue with rowasa . So finally I am off from most of drugs with all the pain and flare up still there and now am lost where to go from here. Can’t give up as my kids are my only hope to hang on to my life.